Maravai Lifesciences Holdings, Inc. (NASDAQ:MRVI)
| Market Cap | $1.98B+89.7% |
| Revenue (ttm) | $213.00M+10.8% |
| Net Income | -$65.67M+45.8% |
| EPS | -$0.45+47.0% |
| Shares Out | 149.25M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,785,366 |
| Open | $7.08 |
| Previous Close | $7.19 |
| Day's Range | $6.91 - $7.16 |
| 52-Week Range | $2.80 - $9.42 |
| Beta | 0.63 |
| Analysts | Buy |
| Price Target | $9.50(+36.10%) |
| Earnings Date | Feb 24, 2027 |
About MRVI
Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product line supports critical stages of biopharmaceutical development, featuring nucleic acids for both diagnostic and therapeutic applications, antibody-based solutions for detecting impurities in biopharmaceutical manufacturing, and tools for monitoring protein expression across different tissue types. The company conducts its operations through two distinct segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment specializes in manufacturing and distributing products integral to gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This encompasses reagents utilized in the chemical synthesis, modification, labeling, and purification of DNA and RNA. Additionally, this division provides messenger RNA, oligonucleotides, their foundational building blocks, plasmid DNA, and the proprietary CleanCap capping technology. Meanwhile, the Biologics Safety Testing segment offers analytical products vital for developing biologic manufacturing processes. Its offerings include bespoke antibody and assay development services tailored to specific products, alongside HCP ELISA kits, various other ELISA kits for identifying bioprocess impurities and contaminants, ancillary reagents, and custom service solutions. Maravai's clientele spans biopharmaceutical companies, other life sciences and biopharmaceutical research firms, academic research institutions, and in vitro diagnostics companies. Incorporated in 2020, Maravai LifeSciences Holdings, Inc. maintains its headquarters in San Diego, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
2 firms rating MRVI in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 24, 2027Earnings report
$MRVI stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in MRVI holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by MRVI's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
MRVI Estimated quarterly lobbying spending
Source: U.S. Senate LDA
MRVI Revenue by Segment or Geography
| TriLink | $28.35M | 61.83% |
| Cygnus | $17.50M | 38.17% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New MRVI patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to MRVI from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in MRVI
| VTIVanguard Morningstar Total Stock Market ETF | $22.81M |
| IWMiShares Russell 2000 ETF | $21.27M |
| VXFVanguard Extended Market ETF | $11.20M |
| IWNiShares Russell 2000 Value ETF | $7.48M |
| FYCFirst Trust Small Cap Growth AlphaDEX Fund | $6.45M |
| IBBiShares Biotechnology ETF | $6.00M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from MRVI’s recent data — informational, not investment advice
What’s Behind the Score
News check: KeyBanc upgrade to Overweight with $11 price target signals analyst confidence in MRVI's prospects.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| FESC | First Eagle Small Cap Equity ETF | 0.98% |
| NIXT | Research Affiliates Deletions ETF | 0.89% |
| GNOM | Global X - Genomics & Biotechnology ETF | 0.62% |
| FYC | First Trust Small Cap Growth AlphaDEX Fund | 0.51% |
| AESB | Harbor AlphaEdge Small Cap Core ETF | 0.28% |
| FYX | First Trust Small Cap Core AlphaDEX Fund | 0.24% |
| FSCC | Federated Hermes MDT Small Cap Core ETF | 0.17% |
| FSEV | Fidelity Enhanced Small Cap Value ETF | 0.16% |
| KOMP | State Street SPDR S&P Kensho New Economies Composite ETF | 0.14% |
| FAD | First Trust Multi Cap Growth AlphaDEX Fund | 0.10% |
| GINN | Goldman Sachs Innovate Equity ETF | 0.10% |
| VFMO | Vanguard U.S. Momentum Factor ETF | 0.10% |
Weight is the stock’s share of each fund’s holdings.
